Get notified when OLMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOlema announces clinical trial collaboration with Bayer for OP-3136 in prostate cancer
Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Olema retains full global commercial and marketing rights to OP-3136 despite collaboration; clinical data and inventions from the combination therapy will be jointly owned with Bayer
Item 8.01 verify on EDGAR → -
high
Phase 1b/2 trial will test OP-3136 (Olema's KAT6 inhibitor) combined with Bayer's NUBEQA in ~36 patients with metastatic castration-resistant prostate cancer, assessing safety and anti-tumor activity
Item 8.01 verify on EDGAR → -
medium
Trial expected to start in second half of 2026; Bayer will supply darolutamide while Olema leads study execution, marking first clinical collaboration for OP-3136
Item 8.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade OLMA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 28, 2026 · How we verify